Towards a vaccine against Ebola virus
- PMID: 14711361
- DOI: 10.1586/14760584.2.6.777
Towards a vaccine against Ebola virus
Abstract
Ebola virus infection causes hemorrhagic fever with high mortality rates in humans and nonhuman primates. Currently, there are no vaccines or therapies approved for human use. Outbreaks of Ebola virus have been infrequent, largely confined to remote locations in Africa and quarantine of sick patients has been effective in controlling epidemics. In the past, this small global market has generated little commercial interest for developing an Ebola virus vaccine. However, heightened awareness of bioterrorism advanced by the events surrounding September 11, 2001, concomitant with knowledge that the former Soviet Union was evaluating Ebola virus as a weapon, has dramatically changed perspectives regarding the need for a vaccine against Ebola virus. This review takes a brief historic look at attempts to develop an efficacious vaccine, provides an overview of current vaccine candidates and highlights strategies that have the greatest potential for commercial development.
Similar articles
-
Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.J Virol. 2006 Mar;80(6):2738-46. doi: 10.1128/JVI.80.6.2738-2746.2006. J Virol. 2006. PMID: 16501083 Free PMC article.
-
Ebola virus: from discovery to vaccine.Nat Rev Immunol. 2003 Aug;3(8):677-85. doi: 10.1038/nri1154. Nat Rev Immunol. 2003. PMID: 12974482 Review.
-
[Hope for a vaccine against ebola virus].Pharm Unserer Zeit. 2001;30(3):185-6. Pharm Unserer Zeit. 2001. PMID: 11400662 German. No abstract available.
-
Development of a preventive vaccine for Ebola virus infection in primates.Nature. 2000 Nov 30;408(6812):605-9. doi: 10.1038/35046108. Nature. 2000. PMID: 11117750
-
Treatment of Marburg and Ebola hemorrhagic fevers: a strategy for testing new drugs and vaccines under outbreak conditions.Antiviral Res. 2008 Apr;78(1):150-61. doi: 10.1016/j.antiviral.2008.01.152. Epub 2008 Feb 26. Antiviral Res. 2008. PMID: 18336927 Review.
Cited by
-
Successful topical respiratory tract immunization of primates against Ebola virus.J Virol. 2007 Jun;81(12):6379-88. doi: 10.1128/JVI.00105-07. Epub 2007 Apr 11. J Virol. 2007. PMID: 17428868 Free PMC article.
-
The evolving field of biodefence: therapeutic developments and diagnostics.Nat Rev Drug Discov. 2005 Apr;4(4):281-97. doi: 10.1038/nrd1694. Nat Rev Drug Discov. 2005. PMID: 15803193 Free PMC article. Review.
-
Stimulation of Ebola virus production from persistent infection through activation of the Ras/MAPK pathway.Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17982-7. doi: 10.1073/pnas.0809698105. Epub 2008 Nov 3. Proc Natl Acad Sci U S A. 2008. PMID: 18981410 Free PMC article.
-
Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species.PLoS Pathog. 2010 May 20;6(5):e1000904. doi: 10.1371/journal.ppat.1000904. PLoS Pathog. 2010. PMID: 20502688 Free PMC article.
-
Development of RNA aptamers targeting Ebola virus VP35.Biochemistry. 2013 Nov 26;52(47):8406-19. doi: 10.1021/bi400704d. Epub 2013 Nov 14. Biochemistry. 2013. PMID: 24067086 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
